Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Biogen Idec's MS Drug Appears to Have an Edge

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

Biogen Idec's (Nasdaq: BIIB  ) first-quarter profit soared 35.4% to $294 million, but even such strong financial results weren't the news of the day for the biotechnology company.

Biogen Idec executives revealed strong phase 3 clinical trial results for experimental multiple sclerosis drug BG-12, which sent shares of the Weston, Mass.-based company to a 52-week high of $106.99. Shares closed Thursday at $99.70, up 13% over Wednesday's close. Biogen Idec already manufactures MS drugs Tysabri and Avonex at its facility in Research Triangle Park, N.C. Growing sales of both drugs led to the strong financial results for the quarter. If BG-12 proves successful, perhaps Biogen Idec could add a third MS drug to its RTP operations and further strengthen the company's position in MS therapies.

Biogen Idec had signaled earlier this month that it had good news on BG-12. So why all the buzz on BG-12? Avonex is an injectable drug; Tysabri is administered through an intravenous infusion. BG-12 is a pill, and the strong results give Biogen Idec an early lead in the growing market for oral MS drugs, The Wall Street Journal reported.

BG-12 would compete against Gelenya, a pill from Novartis (NYSE: NVS  ) , and experimental drug Laquinimod, a pill that is being developed by Teva Pharmaceutical (Nasdaq: TEVA  ) . Biogen Idec CEO George Scangos said on a conference call with analysts that the drug cut relapses by 49% after two years, a reduction of the annual relapse rate of 53%. BG-12 also appeared to reduce progression of MS by 38%.

No head-to-head drug trials have been conducted, but BG-12's initial results show that it appears to be more effective than Laquinimod. Aaron Gal, an analyst at Sanford Bernstein, told Reuters that BG's trial results position the drug candidate well against Laquinimod as well as other oral drugs. We'll know more soon. A second study of BG-12 is planned for later this year.

Want to read more about Biogen Idec? Add it to My Watchlist, which will find all of our Foolish analysis on this stock.

Novartis AG and Teva Pharmaceutical Industries are Motley Fool Global Gains recommendations. The Fool owns shares of Teva Pharmaceutical Industries. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1480263, ~/Articles/ArticleHandler.aspx, 10/22/2016 3:57:30 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 18 hours ago Sponsored by:
DOW 18,145.71 -16.64 -0.09%
S&P 500 2,141.16 -0.18 -0.01%
NASD 5,257.40 15.57 0.30%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/21/2016 4:00 PM
BIIB $290.65 Down -9.01 -3.01%
Biogen CAPS Rating: *****
NVS $75.54 Down -0.38 -0.50%
Novartis CAPS Rating: ****
TEVA $44.00 Down -0.21 -0.48%
Teva Pharmaceutica… CAPS Rating: ****